Want to see OFIX full AI Analyst Report?
Revenue by Segment
Breaks down sales across Orthofix’s business lines (such as spinal products, orthopedics, and adjunct therapies), showing which products or segments are driving growth and which are lagging. Understanding the segment mix helps assess diversification, dependency on key product areas, and how new launches or acquisitions could shift future revenue.Since early‑2023 Global Spine has been the clear growth engine—sales stepped up materially and remain the dominant contributor—while Global Orthopedics, though much smaller, has shown steady acceleration through 2024–25. Management attributes momentum to prioritized distributor relationships, better field execution and upcoming product launches (TrueLok Elevate, Fitbone, VIRATA), which underpin the reaffirmed 2026 guidance. Watch points: lingering biologics softness, timing/stocking variability and modest near‑term EBITDA/cash generation (plus legal settlement risk) could limit upside despite spine strength.
Date | Global Spine | Global Orthopedics |
|---|---|---|
Jun 30, 2026 | $173.24M | $37.69M |
Mar 31, 2026 | $163.85M | $32.86M |
Dec 31, 2025 | $181.93M | $37.98M |
Sep 30, 2025 | $172.06M | $33.57M |
Jun 30, 2025 | $169.82M | $33.30M |
Mar 31, 2025 | $163.84M | $29.81M |
Dec 31, 2024 | $179.88M | $35.77M |
Sep 30, 2024 | $166.10M | $30.50M |
Jun 30, 2024 | $168.03M | $30.59M |
Mar 31, 2024 | $161.29M | $27.32M |